The challenges in paediatric pulmonary arterial hypertension by Beghetti, Maurice & Berger, Rolph M. F.
  
 University of Groningen
The challenges in paediatric pulmonary arterial hypertension





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Beghetti, M., & Berger, R. M. F. (2014). The challenges in paediatric pulmonary arterial hypertension.
European Respiratory Review, 23(134), 498-504. https://doi.org/10.1183/09059180.00007714
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
The challenges in paediatric pulmonary
arterial hypertension
Maurice Beghetti1 and Rolf M.F. Berger2
Affiliations: 1Paediatric Cardiology Unit, Children’s University Hospital Geneva, Geneva, Switzerland. 2Centre
for Congenital Heart Diseases, Dept of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical
Centre Groningen, University of Groningen, Groningen, The Netherlands.
Correspondence: Maurice Beghetti, Unite´ de cardiologie Pe´diatrique, Hopital des Enfants, Cardiologie
pe´diatrique, Rue Willy-Donze´ 6, 1205 Geneva, Switzerland. E-mail: maurice.beghetti@hcuge.ch
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting both adults
and children. While overall survival has improved in recent years, the need for improved therapeutic
approaches remains. Treatments for paediatric PAH have not yet been sufficiently examined, particularly
regarding potential toxicities and optimal dosing, and there is a lack of appropriate clinical trial end-points
and validated treatment goals that might enable a goal-oriented therapeutic approach. Adult randomised
controlled trials in PAH are demonstrating a shift towards more long-term designs, focusing on mortality
and morbidity end-points rather than changes in 6-min walking distance. However, such trial designs may
not be feasible within the paediatric setting due to challenges such as sufficient recruitment and retention of
paediatric patients. Consideration should, therefore, be given towards identifying optimal end-points for
the paediatric population, allowing sufficient duration to evaluate efficacy and safety of potential treatments.
Herein we consider some of the complexities involved in the management of paediatric PAH, specifically
presenting diagnostic challenges as well as reflecting on the lack of evidence currently available to support
various therapeutic approaches within the paediatric population.
@ERSpublications
Paediatric pulmonary arterial hypertension: towards consistency in management and improved
patient outcomes http://ow.ly/Cydpv
Introduction
Pulmonary arterial hypertension (PAH) is a rare disease of the cardiopulmonary system that can be
diagnosed at any age. It is characterised by progressive proliferation and remodelling of the pulmonary
vasculature, causing increased pulmonary vascular resistance (PVR) that ultimately leads to right ventricular
failure [1]. Evidence for the epidemiology of PAH originates primarily from adult registries; however,
several large, international registries have provided further understanding of the disease in the paediatric
population [2–7].
Paediatric PAH is associated with a variety of underlying diseases and causes [5]. The disease is progressive,
with the exception of persistent pulmonary hypertension in the newborn [8], spanning from infancy to
adulthood and is associated with a poor prognosis; therefore, it is important for physicians to deliver the
best possible care according to age for each patient.
Treatment of paediatric PAH is largely based on evidence from studies in adults and on the experience of
clinicians in treating children. Diagnostic and therapeutic strategies for paediatric PAH have not been
sufficiently examined, particularly with regard to potential toxicity and optimal dosing, and there is a lack of
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appropriate clinical trial end-points, hampering trials examining efficacy in children. Furthermore, there is a
lack of appropriate treatment targets that would allow for goal-oriented treatment strategies in children.
This review will focus on the challenges faced by physicians in paediatric PAH, including the complexities of
diagnosis and the limited evidence for effective PAH therapies in the paediatric population.
Paediatric PAH
Pulmonary hypertension characterisation and classification
Paediatric pulmonary hypertensive vascular disease is multifactorial and highly heterogeneous (fig. 1).
While this disease shares some characteristics with PAH in adults, there are differences in associated
conditions and comorbidities, co-existence of genetic or developmental disorders, and the broader context
of growth and development (including underdevelopment and maladaptation). These differences suggest
that the current classification, designed for adult PAH, does not suffice or requires the incorporation of
dedicated paediatric aspects, particularly considering the effect such characteristics may have on diagnosis
and treatment options for paediatric patients.
A Paediatric Taskforce of the Pulmonary Vascular Research Institute has proposed a diagnostic
classification consisting of 10 main classes and 109 subclasses of this disorder, demonstrating its complex
pathophysiology during growth [9].
With the aim to work on the creation of a common disease classification for both adults and children, a
consensus from the 2013 World Symposium on Pulmonary Hypertension has updated the clinical
classification of pulmonary hypertension and added several specific items related to paediatric pulmonary
hypertension [10]. These include the addition of novel genetic disorders causing PAH, the repositioning of
persistent pulmonary hypertension in the newborn as a separate subcategory within Group 1 PAH, the
addition of congenital disorders involved in pulmonary hypertension due to left heart disease, and the
emphasis of developmental lung diseases in Group 3 PAH, as a result of an increased understanding of lung
structure and abnormal vascular growth in these disorders [10]. Currently, this classification has five main
groups of pulmonary hypertension, each of which shares similar pathophysiological, histopathophysiolo-
gical and clinical characteristics. While this approach falls short of an ideal classification for paediatric
pulmonary hypertension, it has the advantages of: assisting consistent diagnosis and treatment; ensuring
standardisation of registry data and improving trial conduct in homogeneous patient groups; and fostering
improved communication amongst physicians, particularly during the transition from infancy to
adulthood.
PAH aetiology and survival
The international TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) registry
shows that, of 362 children with PAH, 57% had idiopathic PAH (IPAH) or familial PAH, a proportion
similar to that observed in adult registries [5, 11, 12]. PAH associated with congenital heart disease (CHD)
is relatively more frequent in children (36%) than adults (10–11%) [5], while PAH associated with
connective tissue disease and other associated forms are very rare in children compared with the adult












FIGURE 1 Multifactorial causes of
paediatric pulmonary hypertensive
vascular disease. Reproduced from [9]
with permission from the publisher.
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Paediatric PAH seems to be associated with a similar life expectancy to that seen in adults [14]. The
REVEAL (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease
Management) registry reported mean¡SD 1-, 3- and 5-year estimated survival rates of 96¡4%, 84¡5%
and 74¡6%, respectively, for childhood-onset PAH [3, 15]. However, most of these patients were
prevalent, and survival for incident patients may indeed be worse due to survival bias. Although overall
survival has improved in recent years for certain patient populations, such as those with repaired CHD and
pulmonary hypertensive vascular disease, poor prognosis remains [4, 16, 17].
Prognostic factors in paediatric PAH patients
A list of currently known prognostic risk factors is included in table 1. Some of these factors mirror those
seen in adults, such as right ventricular failure or progression to World Health Organization (WHO)
functional class III or IV [18]. Specific haemodynamic variables, such as systemic cardiac index
,2.5 L?min-1?m-2, mean pulmonary arterial pressure/mean systemic arterial pressure .0.75 mmHg, right
atrial pressure .10 mmHg or PVR index .20 Wood Unit?m-2, are associated with worse prognosis in
paediatric patients [18]. There are conflicting reports regarding the predictive value of the 6-min walk test
in children with PAH [7, 16, 19, 20]. Emerging evidence indicates that the serum level of B-type natriuretic
peptide or N-terminal pro-brain natriuretic peptide (NT-proBNP) is associated with exercise capacity
[21–23] and predicts prognosis [24]. Specific to paediatric patients, failure to thrive has been reported to be
associated with a higher risk of death [7]. A prospective follow-up study of 66 treatment-naı¨ve paediatric
patients with PAH examined the value of various clinical, biochemical and echocardiographic
measurements in predicting transplant-free survival. Treatment-induced changes in WHO functional class,
NT-proBNP and tricuspid annular plane systolic excursion (TAPSE) were associated with improved
survival [25].
Challenges associated with diagnosis of PAH in children
Results from the TOPP registry revealed that a full diagnostic work-up is rarely performed in paediatric
patients with suspected pulmonary hypertension [5], possibly due to the difficulty of ensuring cooperation
in paediatric patients or the associated risks of certain procedures (such as heart catheterisation, magnetic
resonance imaging or lung biopsy) [2].
Diagnostic work-up (observed symptoms and diagnostic testing) of paediatric PAH is, in principle, similar
to that utilised in the adult population [18]. Right heart catheterisation is essential for PAH diagnosis (using
the same haemodynamic definition as in adults). This may include acute vasoreactivity testing, which has
been shown in some studies to be associated with higher response rates in paediatric patients than adults
[26]. This finding has not been reproduced consistently, however, and may be an artefact of different
criteria used in different studies [7, 27]. While important, diagnostic heart catheterisation may be more
frequently associated with more complications in children than in adults and as such requires specific
expertise [2].
TABLE 1 Determinants of risk in paediatric pulmonary arterial hypertension
Determinants of risk Lower risk Higher risk
Clinical evidence of RV failure No Yes
Progression of symptoms No Yes
Syncope No Yes
Growth Failure to thrive
WHO functional class I, II III, IV
BNP/NT-proBNP Minimally elevated Significantly elevated, increasing
Echocardiography Severe RV enlargement/dysfunction
Pericardial effusion
Haemodynamics Systemic CI .3.0 L?min-1?m-2 Systemic CI ,2.5 L?min-1?m-2
mPAP/mSAP ,0.75 mmHg mPAP/mSAP .0.75 mmHg
Acute vasoreactivity RAP .10 mmHg
PVRI .20 WU?m-2
RV: right ventricular; WHO: World Health Organization; BNP: B-type natriuretic peptide; NT-proBNP: N-
terminal pro-BNP; CI: cardiac index; mPAP: mean pulmonary artery pressure; mSAP: mean systemic artery
pressure; RAP: right atrial pressure; PVRI: pulmonary vascular resistance index; WU: Wood unit. Reproduced
from [18] with permission from the publisher.
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Echocardiography is an important noninvasive tool for the diagnosis of PAH, since it can indicate elevated
pulmonary artery pressure [25, 28, 29]. However, echocardiography is not a substitute for right heart
catheterisation since it cannot properly measure pulmonary artery pressure, PVR and pulmonary capillary
wedge pressure [29, 30]. Therefore, right heart catheterisation is still required to confirm the diagnosis of
PAH. Echocardiography is also useful for patient follow-up once therapy has been initiated [28], and is used
for both assessing and predicting outcomes in paediatric patients through, for example, the measurement of
right/left ventricle ratio and right ventricle stroke work [29, 31]. Changes in TAPSE are also of prognostic
value [25].
Evidence for treatment of paediatric PAH
Compared to the evidence base in adults, the evidence base for paediatric PAH therapy is currently limited
[18]. As a result, the recently proposed IPAH/heritable PAH treatment algorithm (fig. 2) is primarily based
on expert opinion [18]. As a first step, referral to an expert centre is recommended. As disease awareness
increases, there is a possibility that children with suspected PAH may, in some cases, be started on initial
treatment by paediatric cardiologists or respirologists in place of immediate referral to a pulmonary
hypertension centre. This practice may impact on the diagnosis of rarer subtypes of pulmonary (arterial)
hypertension, restrict or prevent inclusion in national disease registries and, in some cases, delay timely
treatment intensification. The decision to use supportive therapies such as warfarin as an anticoagulant,
diuretics for symptomatic management of right ventricle volume overload, oxygen to maintain .90%
oxygen saturation or digoxin to increase cardiac output, should be based on an individual patient’s
requirements, but specific studies to support this remain scarce [18]. Following a full diagnostic work-up,
patients who may be eligible for long-term, oral calcium channel blocker (CCB) therapy should undergo
acute vasoreactivity testing and, in the presence of a positive response, may commence CCB therapy [26].
For non-vasoreactive patients or those failing to respond to CCB therapy, the approach to treatment is
currently based on risk of death (table 1), with lower risk patients typically commencing oral monotherapy.
Data regarding the efficacy and safety of PAH-targeted monotherapy in children are limited to endothelin
receptor agonists [32, 33], intravenous or subcutaneous prostanoids [34], and the phosphodiesterase type-5
(PDE5) inhibitors sildenafil [35, 36] and tadalafil [37]. Sildenafil is currently the only approved treatment in
Europe for PAH in children, based on data from the 16-week STARTS-1 (Sildenafil in Treatment-Naı¨ve
Children, Aged 1–17 Years, with Pulmonary Arterial Hypertension) trial, reporting improvements in peak
oxygen consumption (primary end-point) at higher sildenafil doses [36]. Unexplained increased mortality
was observed in patients receiving higher doses of sildenafil during the trial extension STARTS-2 [35].

























ERA or PDE-5i (oral)
Yes
No
NegativePositive ≥1  year of age
FIGURE 2 The recently proposed paediatric idiopathic/hereditable pulmonary arterial hypertension treatment algorithm.
In Europe, the use of all agents is considered off-label in children, aside from sildenafil. CCB: calcium channel blocker;
ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase type-5 inhibitor. Reproduced from [18] with permission
from the publisher.
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The investigation of treatment in paediatric PAH has highlighted the potential for differences to adults in
pharmacokinetics and dose response [32].
Higher risk paediatric patients may be considered for combination therapy. Registry data suggest a potential
clinical benefit for combination therapy compared with monotherapy in paediatric PAH [38]. The addition
of an inhaled prostacyclin to endothelin receptor agonists or PDE-5 inhibitors may be beneficial; however,
this is based on evidence from a retrospective study of 22 patients across five pulmonary hypertension
clinics [39]. In cases of paediatric patients at higher risk of deterioration, switching to i.v. prostacyclin
should be considered [34, 40]. For patients in WHO functional class IV, patients should be started on i.v.
prostacyclin, potentially in combination with oral endothelin receptor agonists or PDE-5 inhibitors.
In cases where drug therapy does not prevent worsening of PAH, surgical alternatives may be utilised. Atrial
septostomy may be considered as an alternative to transplantation. The Potts shunt has also been shown to
improve functional status and survival in severely ill children [41].
It is clear that while improvements have been and continue to be made in our understanding of treatments
for paediatric PAH, these are currently primarily based on registry data, complemented by individual
clinical experience, short-term trials and open-label studies. In order to make progress towards safe,
effective therapies in paediatric PAH, it is important to understand the difficulties associated with collecting
clinical evidence in this population.
Challenges of clinical trials in paediatric PAH
The relative lack of evidence for treatments in paediatric PAH, compared to the adult population, is
fundamentally linked to challenges in designing and conducting clinical trials that cover a wide range of ages
and stages of development. Normal physical development throughout childhood and adolescence leads to
changes in hormone levels and metabolism, resulting in potential changes in pharmacokinetic and/or
pharmacodynamic parameters [21]. As a result, there is a need for trials that investigate the long-term safety of
PAH-targeted treatments, particularly considering the example of unanticipated dose responses observed
previously [35]. The particular issues associated with such trials can be broadly grouped into regulatory
requirements, defining a homogeneous study population and lack of validated end-points in this population.
Regulatory requirements
The European Medicines Agency (EMA) and the US Food and Drug Administration have issued guidelines
for the conduct of randomised controlled trials (RCTs) in paediatric PAH. EMA guidelines require strong
pharmacokinetic/pharmacodynamic and safety data to be provided; consequently, a number of
pharmacokinetic and safety studies have been initiated, but no RCTs of efficacy have been conducted.
The EMA advocates the extrapolation of results from adults to children with PAH if efficacy is proved in
adults and the disease in children is comparable; however, a dose-finding study is required and a stepwise
approach recommended, beginning with older children in the first instance. The Food and Drug
Administration requires a powered RCT to be conducted in the paediatric pulmonary hypertension setting
with a significant clinical end-point for evidence of efficacy. Therefore, to design a feasible RCT, surrogate
end-points are needed. Haemodynamic parameters are currently not accepted as a surrogate due to the
potential risks associated with cardiac catheterisation in children. 6-min walking distance (6MWD) has
been accepted, but it is difficult to measure consistently, particularly in younger children. Noninvasive end-
points that require further evaluation in paediatric patients include echocardiographic parameters such as
the systolic to diastolic duration ratio, tissue Doppler indices, eccentricity index and TAPSE [18]. TAPSE
improvement has recently been reported as being a valuable goal to reach for children with PAH [25].
Further work is needed to validate echocardiographic parameters as potential treatment goals for paediatric
patients with PAH. Other end-points, such as time to clinical worsening, may be considered; however, this
would require a significant number of patients to be recruited, which remains a challenge in the paediatric
population. In addition, a pure morbidity/mortality study, such as recent adult studies, would be ideal but
again they face the problems of recruitment and length of study. Taken together, these issues highlight the
difficult task of balancing expectations regarding recruitment and retention, with the identification of
clinically meaningful trial outcomes.
Recruitment and retention
RCTs in paediatric PAH face ethical challenges such as the feasibility of a placebo-controlled trial in patients
who may benefit from additional treatments that are often used off-label in clinical practice [42]. In addition
to the lack of validated clinical trial end-points, which is a specific consideration in paediatric PAH [42], other
challenges in designing rigorous trials include duration (given the wide age range and survival rates of
paediatric patients) and, importantly, identifying patients on similar background monotherapy. Recruitment
is exacerbated by disease rarity and the heterogeneity of PAH in infants and children; in addition to a tendency
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to focus on patients without shunts, which significantly reduces the number of eligible patients. This problem
is highlighted by registry findings. Of the 600 patients in the TOPP registry, only 3% were included in clinical
trials [5].
Clinical trial end-points
In order to design meaningful clinical trials for children with PAH, a consensus must be reached on clinical
end-points or treatment goals that are applicable across paediatric age groups and can be clearly linked to
clinical outcomes. Patient registries that specifically aim to assess the appropriateness of treatment variables,
via a standardised collection process, will provide further clarity on such end-points [25].
Adult RCTs in PAH are showing a shift towards more long-term designs, focusing on mortality and
morbidity end-points rather than changes in the 6MWD. Such trial designs may not be possible in the
paediatric setting due to the low numbers of patients that could potentially be recruited, particularly
considering the power required to examine relatively infrequent events such as mortality. This limited
patient pool is further reduced when considering longer term studies, as paediatric patients in clinical trials
may not remain on a single therapy for a prolonged period of time due to advances in standard of care. In
spite of this challenge, long-term safety follow-up is of importance in determining the effects of PAH-
specific therapies on growth, puberty and fertility in paediatric patients [21].
Challenges in exercise capacity or cardiopulmonary exercise testing in the younger or uncooperative child
remain [21], while the performance of echocardiography has not yet been sufficiently studied in children or
adults. In addition, it may be difficult to reproduce findings in multicentre trials accurately. Cardiac
catheterisation, while a more reliable means of assessing disease severity in children, is invasive, often requires
sedation or general anaesthesia and carries a higher risk of complications in children than in adults [43].
Biomarkers offer the potential of a reliable, age-independent indicator of disease severity, with the use of
NT-proBNP currently seen as the most promising tool for potential use as a treatment goal in paediatric
PAH [22–25]. Further studies will be required to ascertain the true predictive value of these and other
biomarkers in individual patients [21]. Based on current evidence, it appears likely that the use of a
combined end-point may be the most appropriate strategy for studies in the paediatric population.
Conclusion
In spite of the challenges inherent to the treatment of paediatric PAH patients and the limited evidence
available, physicians, pharmaceutical companies and regulators continue to take steps to improve treatment
availability. However, there is still a need for a suitable way to build on the current body of evidence in a
larger paediatric patient population and thereby support the development of treatment strategies for
paediatric PAH.
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